文献速递临床试验与 GCP流行病学与生物统计

大面积核心梗死缺血性卒中发病24小时内血管内取栓的个体患者数据荟萃分析

Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication.
PubMed 文献 · Lancet · 2026-05-07

该系统综述与个体患者数据荟萃分析纳入6项随机试验共1886例大面积核心梗死缺血性卒中患者,比较血管内取栓与药物治疗。

要点

  • 大面积核心梗死(ASPECTS≤5或核心≥50mL)发病24小时内取栓改善90天功能结局。
  • 症状性颅内出血和神经功能恶化两组无显著差异。

核心结论

  • 大面积核心梗死缺血性卒中发病24小时内血管内取栓与药物治疗相比改善功能结局并降低死亡率。
  • 除核心体积≥150mL且发病超过6小时者证据有限外,获益在各ASPECTS和核心体积分层中持续存在。

研究设计与样本

  • 系统综述与个体患者数据荟萃分析,检索PubMed和Embase 2018年3月1日至2025年3月1日发表的随机试验。
  • 纳入6项试验共1886例患者(取栓组944例,药物组942例),均由中央影像核心实验室重新裁定ASPECTS并分析核心体积。
  • 采用两阶段随机效应模型荟萃分析,主要结局为90天mRS分布,使用调整汇总广义优势比(aGenOR)。

主要发现

  • 核心体积≥150mL亚组点估计倾向于取栓,尤其早期时间窗(0-6小时),但95%CI较宽限制了解读。

关键数值与推荐

  • 大面积核心梗死定义为ASPECTS≤5或估计缺血核心体积≥50mL。
  • 纳入时间窗为发病24小时内。
  • 主要结局为90天mRS评分分布,采用调整汇总广义优势比(aGenOR)评估。

临床怎么用

  • 对于大面积核心梗死(ASPECTS≤5或核心≥50mL)且发病24小时内的患者,可考虑血管内取栓以改善功能结局和降低死亡率。
  • 核心体积≥150mL且发病超过6小时的患者获益证据有限,临床决策需个体化。

局限性

  • 核心体积≥150mL亚组样本量可能有限,95%CI较宽,解释受限。
  • 研究仅纳入随机试验,未包含真实世界数据。
  • 部分结局存在缺失数据,采用多重插补处理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with extensive ischaemic change are often excluded from endovascular thrombectomy. We aimed to synthesise the evidence from recent trials in these patients by performing a systematic review and individual patient data meta-analysis to estimate treatment benefit, including within clinical and imaging subgroups. METHODS: In this systematic review and meta-analysis, we searched PubMed and Embase for randomised trials published between March 1, 2018, and March 1, 2025, that evaluated efficacy and safety of endovascular thrombectomy compared with medical management in patients with large-core ischaemic stroke (based on an Alberta Stroke Program Early CT Score [ASPECTS] of ≤5 or estimated ischaemic core ≥50 mL) presenting within 24 h of onset. Individual patient-level data from all eligible trials were obtained. A central imaging core laboratory readjudicated ASPECTS and reanalysed ischaemic core volume. A two-stage meta-analysis with random-effects model was used to evaluate the distribution of 90-day modified Rankin Scale (mRS) scores (the primary outcome) using adjusted pooled generalised odds ratios (aGenORs). Missing data were handled by multiple imputation. Safety outcomes were all-cause mortality within 90-day follow-up and neurological worsening within 24-48 h of randomisation, reported as adjusted pooled relative risk (aRR); and symptomatic intracerebral haemorrhage within 36 h of randomisation (reported as risk difference). Subgroup analyses based on clinical and imaging characteristics were done, including subgroups defined by ischaemic core volume, ASPECTS, and time window from onset to randomisation. The meta-analysis was registered with PROSPERO (CRD420251058584). FINDINGS: We included 1886 patients (944 assigned to endovascular thrombectomy and 942 assigned to medical management) from six trials. Baseline characteristics were similar between treatment groups. At day 90, the distribution of mRS scores was improved in patients in the endovascular thrombectomy group (median score 4 [IQR 3-6]; n=940) versus those in the medical management group (5 [4-6]; n=931; aGenOR 1·63 [95% CI 1·42-1·88], p<0·0001). The endovascular thrombectomy group also had reduced mortality (292 [31·1%]) compared with the medical management group (347 [37·3%]; aRR 0·82 [95% CI 0·70-0·97], p=0·022). No significant differences were observed in symptomatic intracranial haemorrhage (ten [1·1%] of 944 vs nine [1·0%] of 942 patients; pooled unadjusted risk difference -0·17 percentage points [95% CI -1·01 to 0·67], p=0·69) or neurological worsening (197 [22·0%] of 896 patients vs 161 [17·9%] of 899; aRR 1·19 [0·87-1·62], p=0·27). Improved functional outcomes with endovascular thrombectomy were consistent across clinical and imaging subgroups, except for those with an estimated ischaemic core volume of 150 mL or greater, in whom point estimates favoured endovascular thrombectomy, particularly in the early time window (0-6 h), but wide 95% CIs limited interpretation. INTERPRETATION: Endovascular thrombectomy was associated with improved functional outcomes and reduced mortality versus medical management in patients with large-core ischaemic stroke presenting within 24 h of onset. With the exception of very extensive ischaemic changes (core volume ≥150 mL) presenting beyond 6 h, where evidence remains limited, benefit was sustained across ASPECTS and ischaemic core strata for patients presenting up to 24 h after onset. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Sarraj A, Thomalla G, Yoshimura S, et al. Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication. Lancet. 2026. PMID: 42107392. doi:10.1016/S0140-6736(26)00876-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。